Novo Nordisk A/S (FRA:NOV)

Market Cap	184.19B
Revenue (ttm)	42.26B
Net Income (ttm)	13.89B
Shares Out	n/a
EPS (ttm)	3.12
PE Ratio	13.26
Forward PE	12.51
Dividend	1.56 (3.81%)
Ex-Dividend Date	Aug 15, 2025

Volume	15,227
Average Volume	29,022
Open	41.00
Previous Close	41.00
Day's Range	40.83 - 42.14
52-Week Range	35.96 - 107.00
Beta	n/a
RSI	44.05
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NOV

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK